The Texas CPRIT fund commits funding toward cancer research and cancer-fighting product development. The latest tranche of funding was awarded on August 19, 2020. The following San Antonio life science researchers were awarded CPRIT grants:
-Pathological Role of Neuronal Cell Cycle Re-entry in the Development of Chemotherapy-induced Peripheral Neuropathy (UTSA’s Hyoung-gon Lee) – $250,000
-SERBP1, Epigenetic Regulation and Glioblastoma Targeting (UT Health San Antonio’s Luiz Penalva) – $249,968
-Role of HOTTIP lncRNA in Leukemogenesis (UT Health San Antonio’s Mingjiang Xu) – $900,000
-Enhancing Cytarabine Response Through SAMHD1 Inhibition (UT Health San Antonio’s Dmitri Ivanov)- $1,198,659
This round of funding did not include any private companies from San Antonio. Over $25M was awarded to Texas companies outside of San Antonio, so any San Antonio companies doing cancer-related work are encouraged to apply.
